Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Summer;21(2):139-142.
doi: 10.31486/toj.20.0025.

Association of Alopecia Areata With Attention-Deficit/Hyperactivity Disorder Stimulant Medication: A Case-Control Study

Affiliations

Association of Alopecia Areata With Attention-Deficit/Hyperactivity Disorder Stimulant Medication: A Case-Control Study

Tyson A Meaux et al. Ochsner J. 2021 Summer.

Abstract

Background: Both psychiatric disorders and diverse medications used to treat them have been associated with alopecia. The objective of our study was to investigate the existence of an association between attention-deficit/hyperactivity disorder (ADHD) stimulant medication (ASM) and various types of alopecia. Methods: We conducted a retrospective case-control medical record review of patients between the ages of 6 and 18 years seen in dermatology clinics during a 10-year period. Cases included patients diagnosed with alopecia areata (AA), alopecia totalis (AT), or alopecia universalis (AU). We matched 3 controls on age and sex to each case. We reviewed patients' medical records for the following medications: lisdexamfetamine, amphetamine/dextroamphetamine, dexmethylphenidate, and methylphenidate. We examined the association between medications used to treat ADHD and diagnoses of AA, AT, and/or AU by calculating a series of odds ratios and 95% CIs. Results: We identified 124 cases (110 with AA, 11 with AT, and 3 with AU) and 372 controls. We found a strong association between AU and ASM use (P<0.0071). No relationship between ASM use and other types of hair loss was found. Conclusion: Although the sample size of cases with AU was small, we found a significant association between AU and ASM. While further study is needed, practitioners may consider close monitoring of patients with AA who use ASM for the development of worsening disease and discontinue the medication if the patient experiences an increase in hair loss that appears to be progressing to AU.

Keywords: Alopecia; alopecia areata; alopecia universalis; amphetamine; attention deficit disorder with hyperactivity.

PubMed Disclaimer

Similar articles

References

    1. Strazzulla LC, Wang EHC, Avila L, et al. . Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1-12. doi: 10.1016/j.jaad.2017.04.1141 - DOI - PubMed
    1. Singam V, Patel KR, Lee HH, Rastogi S, Silverberg JI. Association of alopecia areata with hospitalization for mental health disorders in US adults. J Am Acad Dermatol. 2019;80(3):792-794. doi: 10.1016/j.jaad.2018.07.044 - DOI - PubMed
    1. Chu SY, Chen YJ, Tseng WC, et al. . Psychiatric comorbidities in patients with alopecia areata in Taiwan: a case-control study. Br J Dermatol. 2012;166(3):525-531. doi: 10.1111/j.1365-2133.2011.10714.x - DOI - PubMed
    1. Parameshwar E. Hair loss associated with fluvoxamine use. Am J Psychiatry. 1996;153(4):581-582. doi: 10.1176/ajp.153.4.581 - DOI - PubMed
    1. Kubota T, Ishikura T, Jibiki I. Alopecia areata associated with haloperidol. Jpn J Psychiatry Neurol. 1994;48(3):579-581. doi: 10.1111/j.1440-1819.1994.tb03017.x - DOI - PubMed

LinkOut - more resources